What is the clinical evidence from this study?

Study design: Review. Population: Pulmonary and extra pulmonary diseases, including COVID-19. Intervention: Modulation of Angiotensin Converting Enzyme-2 (ACE2) and Ang-(1-7).

What question did this study set out to answer?

This review evaluates the biological role of angiotensin converting enzyme-2 (ACE2) and examines the therapeutic potential of its modulation in pulmonary, cardiac, and renal diseases, including COVID-19.

March 6, 2023Medicine and Pharmacy ReportsOpen Access

Role of Angiotensin Converting Enzyme-2 and its modulation in disease: exploring new frontiers

View Full Paper

Ask AI

Bookmark

Key result

Therapeutic modulation of ACE2 and Ang-(1-7), including upregulation by statins, may offer potential benefits in pulmonary and extra-pulmonary inflammatory diseases such as COVID-19.

Why the study?

Modulation of Ang-(1-7) offers potential benefit across acute and chronic inflammatory diseases, but the therapeutic role of ACE2 and its modulation required exploration across pulmonary and extrapulmonary conditions, including COVID-19.

Design

Review

Authors

RMRahul MagazineManipal Academy of Higher Education BCBharti ChogtuManipal Academy of Higher Education ABAnup BhatManipal Academy of Higher Education

Discussion

Member takes

Implication

Supports hypothesis generation for ACE2/Ang-(1-7) modulation in inflammation; leaves open randomized trials before clinical adoption.

Key Points

This review evaluates the biological role of angiotensin converting enzyme-2 (ACE2) and examines the therapeutic potential of its modulation in pulmonary, cardiac, and renal diseases, including COVID-19.
Synthesized molecular and physiological evidence on the renin-angiotensin-aldosterone system, focusing on ACE2-mediated cleavage of angiotensin II into angiotensin-(1-7).
Assessed experimental and clinical studies investigating pharmacological interventions, such as statin-mediated ACE2 upregulation, in acute and chronic inflammatory pathologies.
ACE2 serves as the primary functional receptor mediating SARS-CoV-2 entry while counterbalancing angiotensin II by producing tissue-protective angiotensin-(1-7).
Angiotensin-(1-7) prevents fibrosis and blunts tissue injury across animal models of lung inflammation, cardiomyopathy, and renal dysfunction.
Statin administration upregulates ACE2 expression across multiple organ systems, generating favorable anti-inflammatory and antifibrotic outcomes in experimental and clinical cohorts.

Structured PICO

Intervention

Modulation of Angiotensin Converting Enzyme-2 (ACE2) and Angiotensin-(1-7), including upregulation by statins

Highlights the potential therapeutic benefits of modulating ACE2 and Ang-(1-7) in chronic and acute inflammatory diseases, including COVID-19.

Cite This Study

Magazine et al. (2023) conducted a review in Pulmonary and extra pulmonary diseases, including COVID-19. Modulation of Angiotensin Converting Enzyme-2 (ACE2) and Ang-(1-7) was evaluated. Therapeutic modulation of ACE2 and Ang-(1-7), including upregulation by statins, may offer potential benefits in pulmonary and extra-pulmonary inflammatory diseases such as COVID-19.

synapsesocial.com/papers/6a7dabad8b7e38892f15054c https://doi.org/10.15386/mpr-2345

View Full Paper

Ask AI

Bookmark

Role of Angiotensin Converting Enzyme-2 and its modulation in disease: exploring new frontiers

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Role of Angiotensin Converting Enzyme-2 and its modulation in disease: exploring new frontiers

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider